Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth
- PMID: 33345885
- DOI: 10.1016/j.ajogmf.2020.100166
Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth
Abstract
Background: Progesterone has been used for preventing preterm birth with mixed results. The American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine recommended the use of 17-hydroxyprogesterone caproate for risk reduction of recurrent spontaneous preterm birth based on the results of a multicenter, randomized trial in the United States. However, recent literature lacks consensus for efficacy in the American population. In addition, partial adherence and outcomes thereof are underreported. Hence, the relationship between practical adherence to 17-hydroxyprogesterone caproate and outcomes were evaluated.
Objective: The objective of this study was to evaluate the adherence to 17-hydroxyprogesterone caproate, defined as receipt of greater than 80% of intended injections, at an outpatient maternal-fetal medicine center and its effect on maternal and neonatal outcomes.
Study design: This retrospective cohort study included women older than 18 years with a singleton gestation, history of spontaneous preterm birth who initiated 17-hydroxyprogesterone caproate weekly injections between 16 and 20 weeks' gestational age and delivered between the years 2014 and 2017. Women receiving 17-hydroxyprogesterone caproate injections outside of the clinic were excluded. The primary outcome of adherence and secondary outcomes of gestational age at delivery, birthweight, and neonatal outcomes were analyzed using descriptive data, independent t-test, Mann-Whitney U test, chi-square test, and Fisher exact test, where appropriate, with a P value <.05 being considered significant.
Results: Adherence to 17-hydroxyprogesterone caproate occurred in 38 of 92 (41.3%) women included in the study. At baseline, there was a difference in age between groups of adherent and nonadherent women (adherent: 30.8 years; nonadherent: 27.4 years; P=.002). The rate of spontaneous preterm birth less than 37, 35, and 32 weeks were not significantly different in those who were adherent vs nonadherent to 17-hydroxyprogesterone caproate. There were no differences in gestational age at delivery (adherent: 36.8±2.6 weeks; nonadherent: 36.5±3.8 weeks; P=.66), birthweight (adherent: 2776 g; nonadherent: 2709 g; P=.68), or composite neonatal morbidity (adherent: 18.4%; nonadherent: 20.4%; P=.86) between the adherent and nonadherent groups. Neonatal intensive care unit length of stay was 15.5 days in the adherent group compared with 15 days in the nonadherent group (P=.72).
Conclusion: Real-world adherence to 17-hydroxyprogesterone caproate is suboptimal with less than half of women adherent to in-clinic administration. Adherence to 17-hydroxyprogesterone caproate was not associated with a difference in gestational age at delivery or birthweight compared with nonadherence. Further studies are needed to assess the outpatient administration and benefit of 17-hydroxyprogesterone caproate therapy.
Keywords: 17-hydroxyprogesterone caproate; 17OHPC; Makena; adherence; preterm birth; recurrent preterm birth; urban.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.Am J Obstet Gynecol MFM. 2022 Sep;4(5):100658. doi: 10.1016/j.ajogmf.2022.100658. Epub 2022 May 10. Am J Obstet Gynecol MFM. 2022. PMID: 35562009 Review.
-
Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.Am J Obstet Gynecol. 2022 May;226(5):722.e1-722.e12. doi: 10.1016/j.ajog.2022.02.012. Epub 2022 Feb 19. Am J Obstet Gynecol. 2022. PMID: 35189093 Clinical Trial.
-
Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.Acta Obstet Gynecol Scand. 2019 Feb;98(2):139-153. doi: 10.1111/aogs.13488. Epub 2018 Nov 18. Acta Obstet Gynecol Scand. 2019. PMID: 30339274 Free PMC article. Review.
-
Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.Am J Obstet Gynecol. 2017 Sep;217(3):371.e1-371.e7. doi: 10.1016/j.ajog.2017.05.022. Epub 2017 May 17. Am J Obstet Gynecol. 2017. PMID: 28526452
-
Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.Am J Obstet Gynecol. 2016 Mar;214(3):376.e1-8. doi: 10.1016/j.ajog.2015.12.010. Epub 2015 Dec 12. Am J Obstet Gynecol. 2016. PMID: 26692181 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources